Meeting
2016 Genitourinary Cancers Symposium
Inducible MyD88/CD40 to allow rimiducid-dependent activation for control of proliferation and survival of chimeric antigen receptor (CAR) T cells targeting prostate stem cell antigen (PSCA).
Authors
Kevin Mark Slawin
Bellicum Pharmaceuticals, Houston, TX
Kevin Mark Slawin , Aruna Mahendravada , Nicholas Shinners , Peter Chang , An Lu , Jeannette Crisostomo , Eva Morschl , Joanne Shaw , Sunandan Saha , David M Spencer , Aaron E Foster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 206)
DOI
10.1200/jco.2016.34.2_suppl.206
Abstract #
206
Poster Bd #
H21
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells.
First Author: Aaron E Foster
Poster
2016 ASCO Annual Meeting
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma.
First Author: Sarah Nikiforow
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Antigen-dependent costimulation to improve T-cell therapy for cancer.
First Author: Christopher C. DeRenzo